On Monday, Cognition Therapeutics Inc (NASDAQ: CGTX) opened higher 6.63% from the last session, before settling in for the closing price of $0.57. Price fluctuations for CGTX have ranged from $0.22 to $2.54 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -16.44% annually for the last half of the decade. Company’s average yearly earnings per share was noted 52.62% at the time writing. With a float of $50.00 million, this company’s outstanding shares have now reached $61.97 million.
In an organization with 28 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cognition Therapeutics Inc (CGTX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cognition Therapeutics Inc is 19.35%, while institutional ownership is 9.13%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares.
Cognition Therapeutics Inc (CGTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 52.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.88% during the next five years compared to -16.44% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Check out the current performance indicators for Cognition Therapeutics Inc (CGTX). In the past quarter, the stock posted a quick ratio of 2.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.73, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.28 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Let’s dig in a bit further. During the last 5-days, its volume was 54.56 million. That was better than the volume of 3.84 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 44.29%.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 46.80%, which indicates a significant increase from 43.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0890 in the past 14 days, which was higher than the 0.0449 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3511, while its 200-day Moving Average is $0.4733. However, in the short run, Cognition Therapeutics Inc’s stock first resistance to watch stands at $0.6473. Second resistance stands at $0.6895. The third major resistance level sits at $0.7282. If the price goes on to break the first support level at $0.5664, it is likely to go to the next support level at $0.5277. The third support level lies at $0.4855 if the price breaches the second support level.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
There are currently 61,993K shares outstanding in the company with a market cap of 37.50 million. Presently, the company’s annual sales total 0 K according to its annual income of -33,970 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -8,480 K.
